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REVIEW

Year in review 2011: Critical Care – neurocritical care
Salah G Keyrouz* and Michael N Diringer

Abstract
Contributions from the neurosciences to Critical
Care in 2011 covered an array of topics. We learned
about potential biomarkers for, and the effect of
cerebral oxygen metabolism on, delirium, in addition
to treatment of the latter. A group of investigators
studied surface cooling in healthy awake volunteers,
and incidence of infection associated with therapeutic
hypothermia. The effects of statin and erythropoietin
on stroke were revisited, and the role of adhesion
molecule in the inflammatory reaction accompanying
intracerebral hemorrhage was scrutinized. Biomarkers
in subarachnoid hemorrhage and their relationship
to vasospasm and outcome, and effect of daylight
on outcome in this patient population, as well as a
new meta-analysis of statin therapy were among the
research in subarachnoid hemorrhage. Moreover,
2011 witnessed the publication of a multidisciplinary
consensus conference’s recommendations on
the critical care management of subarachnoid
hemorrhage. Results of studies regarding the
diagnosis and vascular complications of meningitis
were reported. Traumatic brain injury received its
share of articles addressing therapy with hypertonic
saline and surgical decompression, the development
of coagulopathy, and biomarkers to help with
prognostication. Finally, research on the treatment of
Guillain-Barre syndrome in children, prediction of longterm need of ventilatory support, and pathophysiology
of critical illness polyneuropathy and myopathy were
reported.

Introduction
This past year’s contributions from the ﬁeld of Neuroscience to Critical Care have been varied, covering an
array of topics and diseases. These include stroke,
subarachnoid hemorrhage, hypothermia, meningitis,
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peripheral nervous system diseases, and delirium, which
captured the lion’s share. We review these articles,
discuss their scientiﬁc contribution to the ﬁeld, and their
clinical relevance below.

Delirium
Delirium is a common condition in the ICU, though
likely more encountered in general ICU than neurointensive care units. Among other things, it is associated
with increased length of stay and mortality [1,2]. Because
of its high prevalence and morbid consequences, delirium
is an important topic in critical care research. In 2011,
ﬁve articles addressing issues including pathophysiology,
diagnosis and treatment of delirium were published in
Critical Care.
McGrane and colleagues [3] sought to investigate a
possible relationship between serum procalcitonin,
C-reactive protein and delirium. Procalcitonin and
C-reactive protein are inﬂammatory biomarkers that
have been linked to many acute neurological conditions,
like stroke, and other critical illnesses [4]. This prospective cohort study was part of a double-blind, randomized controlled trial comparing dexmedetomidine and
lorazepam for sedation of mechanically ventilated
patients (Maximizing Eﬃcacy of Target Sedation and
Reducing Neurological Dysfunction or MENDS) [5].
Data were analyzed for 87 (of 103) patients enrolled in
MENDS. Higher levels of procalcitonin, but not Creactive protein, were associated with fewer delirium/
coma free days (odds ratio (OR) 0.5, 95% conﬁdence
interval (CI) 0.3 to 1.0; P = 0.04), but neither biomarker
showed a relationship with 28-day survival. Some of
these results were contradicted by another study led by
Van den Boogaard and colleagues [6], which was a prospective observational single center study of 100 critically
ill patients (50 with and 50 without delirium). These
patients were further divided into two groups, ‘inﬂamed’
and ‘non-inﬂamed’ based on the presence of at least two
systemic inﬂammatory response syndrome (SIRS) criteria
and a positive culture. The reason for this dichotomy is
the suspected diﬀerence in levels of inﬂammatory
mediators between the groups. Multivariate regression
analysis showed that IL-8 was independently associated
with delirium in ‘inﬂamed’ patients (OR 9, 95% CI 1.8 to
44; P ≤ 0.05), and similarly IL-10 (OR 2.6, 95% CI 1.1 to
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5.9; P ≤ 0.05) and the amyloid beta protein Aβ1-42/40 (OR
0.03, 95% CI 0.002 to 0.50; P ≤ 0.05) in ‘non-inﬂamed’
patients. Procalcitonin was an important biomarker that
predicted delirium, although this variable did not make it
through the multivariate analysis. Based on these results,
the authors speculate that the pathophysiology of
delirium in diﬀerent patient populations could vary, and
thus potential therapy might need to be more targeted.
Nonetheless, the recent studies prove that, to date, the
optimal biomarker that could predict the occurrence of
delirium remains elusive.
In another prospective observational study investigating the relationship between imbalance in cerebral
oxygen supply/demand ratio and occurrence of delirium,
Schoen and colleagues [7] used near infrared spectroscopy to measure pre- and intraoperative cerebral oxygen
saturation (ScO2) in 231 patients undergoing on-pump
cardiac surgery looking for a relationship between these
measurements and development of post-operative
delirium. In an earlier study, preoperative ScO2 was
associated with postoperative morbidity and mortality in
a similar cohort of patients [8]. The current investigation
found that older age, lower mini mental status
examination (MMSE) score, history of neurologic or
psychiatric disease, and lower preoperative ScO2 were
independent predictors of postoperative delirium,
irrespective of hemoglobin or amino-terminal pro B-type
natriuretic peptide levels, the latter being a marker of
cardiac insuﬃciency. One important limitation of this
study is that it did not account for postoperative analgesia
use, which is a known risk factor for delirium.
Two papers addressed treatment of delirium using
quetiapine. The ﬁrst is a post hoc analysis of a double
blind, randomized, placebo controlled study [9,10]. The
authors had already shown that delirium resolves faster
when quetiapine is added to as-needed haloperidol [9]. In
the current analysis, they sought to investigate the eﬀect
of quetiapine on individual delirium symptoms of the
Intensive Care Delirium Screening Checklist (ICDSC).
Their results suggest that quetiapine may lead to a shorter
time to ﬁrst resolution of symptom ﬂuctuation, inattention, and disorientation, but a longer time to ﬁrst resolution of agitation and hyperactivity. This could be
relevant when one considers that certain symptoms could
be disruptive to patient care and maybe even injurious to
patient and healthcare provider, and hence there is a
greater urgency to control them.
The second article, describing a single institution’s use
of quetiapine in a small cohort of patients with delirium
without comparative analysis, reported a reduction in
need for other antipsychotics once quetiapine was introduced [11]. Adverse events were minor and transient.
Despite the mixed results from these two studies, overall
quetiapine has a beneﬁcial role, at least in alleviating
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certain delirium symptoms and maybe reducing the need
for other, sometimes less benign anti-psychotics.

Hypothermia
Therapeutic hypothermia (TH) has become a standard
practice for out of hospital ventricular ﬁbrillation cardiac
arrest. TH improves neurological outcome when initiated
soon, and maintained for 12 to 24 hours after successful
resuscitation [12,13]. Studies suggest that TH could be
also beneﬁcial in other conditions like stroke and
myocardial infarction [14-16]. Unlike patients who
survive cardiac arrest and are comatose, however, those
suﬀering a stroke or myocardial infarction are awake and
therefore could perceive discomfort during cooling.
Testori and colleagues [17] investigated the feasibility and
safety of inducing mild hypothermia (32 to 34°C) in
healthy conscious volunteers using a novel, non-invasive
surface cooling method. This prospective study, which
was sponsored by the manufacturer of the cooling pads
(EMCOOLSpad®, Emcools AG, Pfaﬀstaetten, Austria),
enrolled 16 healthy men aged 18 to 70 years. The pads
were 20 × 30 cm each and consisted of multiple cooling
cells ﬁlled with a patented cooling gel. They were applied
on the back, thorax, abdomen, and thighs and were
exchanged when thawed. Volunteers were medicated
with meperidine, buspar to combat shivering. The active
cooling and maintenance period was set at 6 hours,
during and after which volunteers’ biomarkers (for
example, esophageal temperature, blood pressure, and so
on), comfort level, and skin condition were monitored.
Although all individuals achieved temperatures <35°C,
a target temperature of 32 to 34°C set by the investigators
was reached in only 6 despite using magnesium sulfate
infusion in some. Cooling pads had to be exchanged
often because they were completely thawed before
reaching temperatures <35°C. Temperature decreased
from baseline median 36.2°C to 35°C within a median
time of 53 minutes (median cooling rate of 1.1°C/h).
Heart and respiratory rates, oxygen saturation and blood
pressure decreased signiﬁcantly during cooling, although
none of the volunteers reported complaints. Furthermore, none felt discomfort that necessitated termination
of cooling. Mild to moderate skin irritation improved
over a follow-up period of 7 days. Shivering occurred in
four volunteers, although increasing the dose of
meperidine easily controlled it.
In conclusion, healthy, conscious volunteers did not
describe active cooling using a novel surface method as
uncomfortable. The method was safe, but only partially
eﬀective; an algorithm diﬀerent from the one used by the
investigators will be needed to achieve preset
temperatures.
To address the issue of infections, a widely feared
complication of TH, Kamps and colleagues [18] studied
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the eﬀect of selective decontamination of the digestive
tract (SDD) in a group of severely brain-injured patients
treated with prolonged mild TH on incidence of
infection. Hypothermia increases the risk of infectious
complications by interfering with leukocyte function and
proinﬂammatory cytokine release [19,20].
This retrospective case-control study compared the
incidence of infectious complications in adults with
severe brain injury treated with TH (n = 35) to those not
treated with TH (n = 169). Cooling was initiated by
chilled Ringer’s lactate infusion and maintained for a
median duration of 107 hours (55 to 168 hours) using
surface methods. Both groups received SDD, which
included intravenous cefotaxim and oropharyngeal and
enteral polymixin, tobramycin, and amphotericin B.
Matching cases and controls using propensity scoring
that was based on known outcome predictors yielded 2
relatively homogenous groups of 35 patients each; however, more patients in the hypothermia group received
parenteral nutrition (68.6% versus 37.1%; P = 0.013), and
the maximum dose of midazolam was higher in that
group too (0.31 ± 0.10 mg/kg/h versus 0.25 ± 0.11 mg/
kg/h; P = 0.043).
Despite a higher rectal (but not oropharyngeal or
bronchial) bacterial colonization rate in the TH group
(51.4% versus 25.7%; P = 0.049), these patients were not
more likely to develop an infectious complication (20%
versus 34.3%; P = 0.267).
Still the potential biases in this study, which include its
retrospective, non-randomized and uncontrolled design,
unbalanced baseline characteristics (for example, parenteral nutrition, more severe intracranial hypertension
necessitating TH, and higher doses of vasoactive drugs),
and higher mortality in the TH group, favor the
normothermia group. Therefore, the results carry some
relevance by making the case for using SDD in braininjured patients at high risk for infectious complications.

Stroke
Despite the availability of acute therapy, ischemic stroke
remains a major public health issue worldwide. This is
partly because of its high prevalence and morbidity,
coupled with the still meager use of intravenous thrombolysis, continuously fueling interest in neuroprotection
and other therapies. Tsai and colleagues [21] investigated
the eﬀect of 3-hydroxy 3-methyl-glutaryl coenzyme-A
(HMG-CoA) reductase inhibitor, or statin, treatment
before and after stroke on platelet function. They
measured expression of CD62P and CD63 surface
molecules [21], which play an important part in platelet
adhesion and activation during and after stroke [22].
The prospective non-randomized and uncontrolled
cohort study compared blood samples and 90-day outcomes of 43 patients who were using diﬀerent forms and
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doses of statins before stroke to those of 129 patients
without pre-morbid statin use (66 patients administered
statins within 72 hours of stroke, and 63 patients not
administered statins). At baseline, patients with preexisting statin use were more likely to have diabetes, and
had signiﬁcantly lower total and low density lipoprotein
cholesterol levels than those who were not taking statins.
In addition, the expression of platelet CD62P and CD63
molecules were, too, signiﬁcantly lower. The expression
of CD62P, but not that of CD63, at days 7, 30, and 90
remained signiﬁcantly lower in the group with preexisting
statin use. Initiation of statins after stroke did not have a
signiﬁcant eﬀect on the expression of these platelet
surface molecules. In a stepwise logistic regression
model, severity of stroke, underlying coronary artery
disease, and pre-existing statin use were independent
predictors of 90-day outcome; however, the conclusion’s
validity is questioned by the small sample size and bias
related to the study design.
In a prospective randomized and placebo-controlled
trial, Yip and colleagues [23] investigated the safety and
eﬀect of yet another drug, erythropoietin (EPO), on
outcome and level of circulating endothelial progenitor
cells (EPCs) following ischemic stroke. Among EPO
actions is mobilization of EPCs. The authors had shown
in a previous study that an increase in circulating levels
of EPCs was associated with a favorable outcome in
patients with ischemic stroke [24].
By comparing patients receiving two doses of 5,000 IU
each of EPO (n = 83) to those receiving placebo (n = 84)
and to age and gender-matched healthy volunteers
(n = 60), the authors reported no adverse events related
to EPO. Baseline EPC levels were higher in patients
suﬀering an ischemic stroke compared to healthy
volunteers. In addition, whereas EPC levels early after
ischemic stroke were comparable between the two study
groups, that level rose signiﬁcantly in the active treatment
group by day 21. Although patients treated with EPO
were more likely to have less disability from their stroke
90 days later, this study did not provide longer-term
follow-up that is more appropriate when considering
events like recurrent stroke. Furthermore, a relationship
between EPC levels and recurrent stroke or death 90 days
after ischemic stroke is unclear.
Intracerebral hemorrhage (ICH) is another, yet
fortunately less common, type of stroke. It is responsible
for a disproportionate number of deaths and staggering
morbidity. Despite interest, enthusiasm and large trials, a
proven therapy for ICH remains elusive. Early morbidity
and mortality from ICH is related to structural damage
caused by the hemorrhage, edema, and inﬂammation.
An increase in levels of circulating adhesion molecules
is thought to contribute to an inﬂammatory response in a
number of diseases aﬀecting the central nervous system.
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Adhesion molecules facilitate movement of activated
mononuclear cells across endothelial cells of the blood
brain barrier [25]. In a retrospective study, Wang and
colleagues [26] revealed that concentrations of soluble
intercellular cell adhesion molecule-1 (sICAM-1) and
vascular cell adhesion molecule-1 (sVCAM-1) were
higher at baseline and increased through day 10 in
patients with hypertensive ICH. Furthermore, sICAM-1
was independently associated with outcome. However,
the latter, deﬁned as a modiﬁed Rankin scale score of 0 or
1, was only measured at discharge. Furthermore, the
patient cohort had relatively small ICH volumes (median
volume of 10 ml). These limitations might have impacted
the study results, which do not oﬀer a clear link between
levels of adhesion molecules, pathophysiology, and
ultimate outcome that should be measured at least
90 days after hemorrhage.

Subarachnoid hemorrhage
Despite its relatively low prevalence, subarachnoid
hemorrhage (SAH) remains a serious illness with high
morbidity and mortality. Securing aneurysms, rupture of
which is to blame for the hemorrhage, has come a long
way. However, our ability to treat the myriad complications that accompany SAH, particularly vasospasm
(VSP) and delayed cerebral ischemia, is still disappointing
[27]. Hence, it is not surprising to read about many
publications addressing SAH and the treatment of its
complications in Critical Care in 2011.
First, a landmark paper published the recommendations
of a Neurocritical Care Society’s multidisciplinary consensus conference on the critical care management of
SAH [28]. Based on the best available evidence, coupled
with their expert opinion, a group of experienced
clinicians and researchers addressed issues including
medical measures to prevent re-bleeding, prophylactic
use of anticonvulsant drugs, monitoring and managing
intravascular volume status and cardiopulmonary complications, temperature and glucose control and sodium
homeostasis, current use of statins and magnesium
sulfate, monitoring and managing delayed cerebral
ischemia, and ﬁnally anemia and transfusion, and endocrine dysfunction in SAH. The purpose of these recommendations is to oﬀer guidance to clinicians when
making diagnostic and management decisions in the
absence of high quality data.
Touching on one of the themes addressed in the
Neurocritical Care Society’s multidisciplinary consensus
conference paper, an updated meta-analysis of six
randomized clinical trials of magnesium sulfate in the
treatment of VSP was carried out by Wong and colleagues
[29]. Magnesium is a physiologic antagonist of calcium
that in in vitro and animal studies causes arterial vasodilation and is neuroprotective [30]. Studies of magnesium
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sulfate in VSP have thus far yielded conﬂicting and largely
disappointing results [31-34]. Not surprisingly, and in
keeping with results of most individual trials, the authors
found no evidence to lend support for a beneﬁcial eﬀect
of magnesium sulfate on the incidence of delayed
ischemic deﬁcits or overall outcome.
Despite meager scientiﬁc evidence, emphasis on availability of natural light in the ICU environment is universal
[35]. An interesting single center study tested the
hypothesis that care in an ICU room with a window
contributes to better outcome in patients with SAH [36].
This was a retrospective study that mined data on 789
patients from a large prospective SAH database at
Columbia University. Care in a room with a window had
no eﬀect on outcome, measured by modiﬁed Rankin
Scale score at discharge, 3 months and 1 year. Furthermore, it had no eﬀect on other secondary endpoints like
length of mechanical ventilation (MV), delirium, ICU
length of stay, and mortality. The results were the same in
a subgroup analysis that included patients admitted
during the months of the year with more than 12 hours of
daylight, and those with better Hunt-Hess grade SAH.
Continuing with outcome studies, a group of investigators assessed the ability of copeptin, the carboxyterminal portion of the arginine vasopressin precursor
peptide, in predicting outcome and incidence of VSP in
patients with SAH [37]. Recent data found that plasma
copeptin levels were elevated in patients with traumatic
brain injury (TBI), ICH and ischemic stroke [38-43].
The authors reviewed medical records of 303 patients
with aneurysmal SAH whose copeptin levels were compared to those of 150 sex- and age-matched healthy
volunteers. Plasma copeptin levels on admission were
signiﬁcantly higher compared to healthy controls
(21.2 ± 9 pmol/L versus 6.4 ± 1.8 pmol/L; P < 0.001). A
multivariate analysis identiﬁed World Federation of
Neurological Surgeons (WFNS) score, modiﬁed Fisher
score, and plasma copeptin levels as independent
predictors of occurrence of VSP, and in-hospital and oneyear mortality. However, copeptin levels did not improve
the predictive power of either WFNS or the modiﬁed
Fisher score when the variables were combined.
Conversely, plasma levels of copeptin, along with WFNS
and modiﬁed Fisher score, independently predicted poor
outcome at one year (deﬁned as a Glasgow Outcome
Scale (GOS) score of 1 to 3), and copeptin signiﬁcantly
added to the predictive power of WFNS (P = 0.018) and
modiﬁed Fisher score (P = 0.029) in this case. Despite
these encouraging results, using copeptin levels to help
with prognostication in SAH is not ready for primetime
yet. Further studies to validate and conﬁrm these ﬁndings
are needed.
Another paper investigated risk factors for VSP in
patients with bleeding from arteriovenous malformations

Keyrouz and Diringer Critical Care 2012, 16:245
http://ccforum.com/content/16/6/245

[44]. While VSP commonly complicates aneurysmal SAH,
its incidence, risk factors and consequences in ruptured
arteriovenous malformation are unknown. A single
center, retrospective observational study from a busy
neurosurgical practice in Paris, France found that of 72
patients with ruptured arteriovenous malformation, 12
(17%) had VSP deﬁned by transcranial Doppler (TCD)
blood ﬂow velocity >120 cm/s in any cerebral artery. Four
patients underwent digital subtraction angiography with
results conﬁrming TCD ﬁndings. Furthermore, 6 (8%) of
the patients with abnormal TCD ﬁndings went on to
develop cerebral infarcts. Multivariate analysis identiﬁed
three risk factors for developing TCD-deﬁned VSP: a low
Glasgow Coma Score (GCS), female gender, and younger
age. Amount of subarachnoid, intraventricular or
intraparenchymal blood had no eﬀect on risk of VSP, and
outcome was not aﬀected by the development of VSP,
though the sample size was small and a possible eﬀect
could not be excluded.
The need for better tools to monitor critically ill
patients, mitigate deterioration before or as they occur,
and predict and improve outcome has led to the
development of an array of neuromonitoring devices to
use in the neurointensive care unit. However, and despite
the enthusiasm those devices have generated, clinicians
have struggled to meaningfully incorporate them in daily
practice to ultimately impact outcome. This is mainly
because of a complex link between monitored function
or marker, intervention and outcome.
A group of researchers studied the utility of combined,
continuous electroencephalogram (EEG) and somatosensory evoked potential (SSEP) recording in 68 critically
ill patients with SAH (51 patients) and ICH (17 patients)
[45]. Recordings were carried out for an average of
10 ± 4 days. As expected, EEG and SSEP changes
preceded clinical deterioration, intracranial pressure
(ICP) elevation, and/or new abnormalities on imaging
studies in the majority of patients. In addition, combined
EEG and SSEP monitoring increased the odds of predicting deaths when deterioration did occur. SSEP and GCS
score changes signiﬁcantly predicted GOS. A caveat to
these ﬁndings is that speciﬁc interventions to prevent
and treat deteriorations were not discussed. Continuous
data monitoring of such tests could prove cumbersome,
and may be impossible in certain settings and
institutions.

Meningitis
Bacterial meningitis is associated with many complications like seizure, hydrocephalus, cerebral venous
thrombosis, empyema, and stroke. These complications
add to the already high morbidity of the disease. Diﬀerent
mechanisms underlie the development of stroke, the
most common being arterial narrowing caused by an
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inﬂammatory vasculitis. Klein and colleagues [46]
reviewed medical records of 94 patients with bacterial
meningitis cared for at one institution looking for the
incidence of arterial narrowing. Patients underwent TCD
of commonly insonated cerebral vessels. Although it is
unclear when and how often TCD was performed, 43% of
patients had elevated systolic Doppler velocities
(222 ± 45 cm/s), almost half of whom were diagnosed
within the ﬁrst two days. The authors found that elevated
TCD velocities were more often seen in sicker patients
and those who were treated with corticosteroids, though
the latter was associated with the former and multivariate
analysis was not performed. In addition, elevated
velocities increased the risk of stroke and poor outcome,
which treatment with nimodipine did not reduce.
Another paper investigated the early diagnosis of
meningitis [47]. Appropriate therapy of bacterial meningitis relies on early diagnosis. Direct cerebrospinal ﬂuid
(CSF) examination only identiﬁes a bacterial pathogen in
60 to 80% of cases, and results of cultures are delayed for
days [48,49]. An earlier study by Viallon and colleagues
[50] suggested that serum procalcitonin and CSF lactate
levels could diﬀerentiate bacterial from viral meningitis
on presentation in patients who have negative direct CSF
examination. Their current study was aimed at validating
the value of these markers in accurately making the
diagnosis of bacterial meningitis upon admission. This
was an observational study comparing patients with
bacterial (n = 35) to those with viral (n = 218) meningitis
treated at one hospital over a span of 12 years. The
authors concluded that a CSF lactate level of 3.8 mmol/L
had a sensitivity of 94% and a speciﬁcity of 97% when
diﬀerentiating the two types of meningitis. Similarly, the
sensitivity and speciﬁcity of a serum procalcitonin of
0.28 ng/ml was 97% and 100%, respectively. Although the
number of patients with bacterial meningitis in this study
is small, the results are nonetheless clinically relevant,
especially when other parameters like leucocyte count,
glucose and protein levels, albeit less sensitive, are also
suggestive of a bacterial etiology. Thus, these ﬁndings
could oﬀer some hope for an earlier diagnosis, and
therefore timely appropriate therapy, in those patients
with unrevealing CSF, or blood, culture results.

Traumatic brain injury
Acute coagulopathy is a dreaded complication of TBI. Its
prevalence ranges between 10% and 90%, depending on
how it is deﬁned, and is more often encountered in
severely injured patients. A retrospective review by a
group of investigators sought to determine the incidence
of coagulopathy in TBI and understand its relationship
with outcome [51]. Of 107 patients with isolated TBI,
65% of whom had severe injury, coagulopathy was
present on admission in 24%. Another 40% of those
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without coagulopathy on admission developed abnormalities in their coagulation parameters within 24 hours
of admission. Coagulopathy upon admission was associated with death (OR 3.75; P = 0.04), though there was
no interaction between severity of TBI and death that
one would expect. Finally, because of its retrospective
nature, information about other consequences and
treatment of coagulopathy was lacking.
An interesting retrospective review by Roquilly and
colleagues [52] described the authors’ 9-year experience
in treating severe TBI-related refractory intracranial
hypertension in 50 patients with an algorithm-guided
continuous hypertonic saline infusion. The authors used
an algorithm that considered natriuresis, diuresis and
patient’s weight, and adjusted the infusion rate of a 20%
saline solution based on intracranial pressure and the
diﬀerence between pre-set and current sodium level.
Though the paper was purely descriptive, the authors
indicated that the approach was successful in quickly
lowering ICP, and did not result in major adverse events.
Validating this algorithm by comparing the approach to
bolus administration of hypertonic saline should be
considered the next step, especially in light of the
controversy regarding the eﬀectiveness of mannitol compared to hypertonic saline and its adverse events [53].
Similarly, surgical management of TBI using a bifrontotemporoparietal decompressive craniectomy was evaluated in a randomized controlled study by Cooper and
colleagues [54]. The long awaited results disappointed
most who are intimately involved in caring for patients
with TBI. The study recruited adult patients with severe
non-penetrating TBI with a GCS between 3 and 8 and
elevated ICP that is refractory to standard therapy.
Patients were randomized within the ﬁrst 72 hours after
TBI to either undergo an extensive decompressive
craniectomy and durotomy plus standard care (n = 73) or
standard care alone (n = 82), while allowing crossover
from the latter to the former group. Decompressive
craniectomy decreased ICP, duration of mechanical
ventilation and ICU length of stay in comparison to
medical therapy alone, although 6-month outcome
measured by the extended GOS was worse in the surgical
group (OR for a worse functional outcome, deﬁned as a
score of 1 to 4 on the extended GOS, was 1.84; 95% CI,
1.05 to 3.24; P = 0.03). This unexpected result could have
been the product of many variables, as suggested by
criticism that the study received; these included enrolling
a small subset of TBI patients with ICP that was not very
elevated, and possibly suboptimal medical management
before craniectomy, long accrual time before surgery, the
operative technique that did not involve division of the
sagittal sinus and falx cerebri, and possibly worsening
vasogenic edema following craniectomy and decompression of the brain. In clinical practice, decompressive

Page 6 of 9

craniectomy in TBI is typically an intervention of last
resort. The results of this study, considering its shortcomings, are unlikely to change the current practice.
Prognostication early in the course of TBI remains a
vexing and frustrating issue. The available tools, including
clinical examination and brain imaging, are far from
being perfect and reliable [55]. A multi-center prospective study investigated the value of serum ubiquitin
C-terminal hydrolase-L1 neuronal protein (UCH-L1),
and glial ﬁbrillary acidic protein (GFAP) levels in
predicting outcome in severe TBI [56]. Eighty-one
patients with severe TBI with or without minor extracranial injury were recruited from four centers. Serial
(every 6 hours) measurements of both serum UCH-L1
and GFAP were collected in the ﬁrst 24 hours and
compared to those from 167 healthy volunteers. The
authors found signiﬁcant elevation in levels of both
biomarkers in their cohort of brain-injured patients. In
addition, GFAP was higher in patients with focal mass
lesions, whereas UCH-L1 was higher in patients with
diﬀuse injury, potentially suggesting diﬀerent susceptibility of neurons and glia to diﬀerent patterns of injury.
Secondary elevations and sustained high levels of either
biomarker within the ﬁrst 24 hours were linked to
secondary insults and surgical intervention. UCH-L1 was
an independent predictor of mortality at discharge; a
level of 1.89 ng/ml had a speciﬁcity and sensitivity of 96%
and 52% in predicting early deaths. Finally, a predictive
model including age, GCS and UCH-L1 levels accurately
classiﬁed patients as dead versus alive at 6 months 94% of
the time. Findings of this study are interesting; if validated
in a larger cohort, a combination of clinical ﬁndings,
brain imaging and biomarkers could aid in early prognostication in patients with TBI.

Peripheral nervous system
A handful of papers published in Critical Care last year
addressed questions related to the peripheral nervous
system. Two of these dealt with Guillain-Barre syndrome
(GBS). The ﬁrst, by El-Bayoumi and colleagues [57],
described the results of a single center randomized trial
of intravenous immunoglobulin (IVIg) versus plasma
exchange (PE) in ventilated children with GBS. In adults,
treatment with IVIg or PE leads to comparable outcomes
[58,59], and similar duration of MV [60]. The aim of the
study was to understand the eﬀect of the two immunotherapies on duration of MV, ICU length of stay and
overall outcome in children. With a small sample size
(IVIg 20 patients; PE 21 patients), the investigators found
that outcome, measured by the ability to ambulate
independently 4 weeks after discharge from ICU, was
similar in the 2 groups; yet children treated with PE had a
signiﬁcantly shorter duration of MV compared to those
treated with IVIg (11 ± 1.5 days versus 13 ± 2.1 days;
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P = 0.037). Conﬁrmation of these ﬁndings by larger
randomized trials could have an important impact on
how we treat children with severe GBS.
The second study sought to answer an important
question that clinicians caring for patients with GBS are
faced with: how to decide early in the course of the illness
who will need a tracheostomy. Fourrier and colleagues
[61] reviewed medical records of 61 adult patients with
GBS treated at their institution between 1996 and 2009.
Of those, 40 patients required MV, 12 for equal or less
than, and 28 for more than 15 days. Three of the 12
patients in the shorter MV group and 25 of the 28
patients in the longer MV group underwent tracheostomy. The authors found that the combination of a
sciatic nerve conduction block on electromyography and
lack of foot ﬂexion after completion of immunotherapy
was an excellent predictor of prolonged MV (100%
speciﬁcity). This ﬁnding awaits validation before being
used to predict prolonged MV and hence the need for
tracheostomy in this patient population.
Critical illness polyneuropathy and myopathy (CIPNM)
is another cause of ﬂaccid paralysis in the ICU, though
unlike GBS, which is the reason for admission, CIPNM
develops during a long ICU stay. The exact pathophysiology of CIPNM is yet to be elucidated, although risk
factors like use of neuromuscular blocking agents,
aminoglycosides, and high dose corticosteroids have
been incriminated [62,63]. More recently, calcium
homeostasis disturbances in critically ill, septic patients
have been suggested to play a role in the pathogenesis of
CIPNM [64].
Anastasopoulos and colleagues [65] prospectively
followed 190 consecutive critically ill patients with ICU
length of stay longer than 7 days who were admitted to
their institution over a 9-month period. Forty of the 190
patients developed CIPNM, which was conﬁrmed by
electromyography. Patients with CIPNM had a longer
duration of MV (32.88 ± 22.2 days versus 14.4 ± 9 days;
P < 0.05) than those without CIPNM. Episodes of prolonged hypocalcemia were common, especially among
patients with septic shock. Logistic regression analysis
showed that hypocalcemia, hypercalcemia and septic
shock were independently associated with the development of CIPNM. The severity of hypocalcemia, however,
did not correlate with that of CIPNM. The proposed
mechanism by which hypocalcemia could lead to CIPNM
involves elevated intracellular calcium concentration
interfering with proteolysis of myosin thick ﬁlament.
Finally, whether hypocalcemia is a cause or byproduct of
severe illness during which CIPNM is more likely to
occur remains unclear, and more studies are needed to
prove a cause-eﬀect relationship.
To evaluate weakness in critically ill patients, clinicians
and researchers use the Medical Research Council
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(MRC) sum score, which is the average MRC strength
score combined for 12 speciﬁed muscle groups [66]. The
feasibility and reliability of this score was tested in
patients with GBS, and in outpatient survivors of critical
illness. A recent study suggested that performing manual
strength testing for the MRC sum score is not feasible in
a large number of patients in the ICU [67]. This is most
often related to impaired attention and comprehension.
In addition, albeit the sample size was small (n = 30) and
patients developing weakness were few, the interobserver
agreement for individual muscle group and the total
MRC sum score was poor, especially when patients were
uncooperative. This study raises an important issue,
given that the MRC sum score is widely used and
reported in investigations of weakness in the ICU. This
leaves room for speculation about the validity of results
of such studies.

Conclusion
The unrelenting interest in neuroscience research was
the impetus behind many good quality investigations
published in Critical Care in 2011. These expanded our
knowledge about delirium, its risk factors and diﬀerent
pathophysiologic mechanisms, therapy for vasospasm,
and stroke, complications of TBI, diagnosis of meningitis,
and respiratory failure in GBS. Some of these articles
could be the precursor to larger trials that advance our
knowledge of diseases, their treatment and outcome in
the neurointensive care unit.
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